Intervacc AB operates under a unique business model focused on the development and commercialization of innovative vaccines for livestock animals. By leveraging advanced biotechnology and immunology, Intervacc aims to provide effective and safe solutions to prevent and control infectious diseases prevalent in animal populations. Through research, development, and collaboration with industry partners, Intervacc seeks to address key challenges in animal health and contribute to sustainable farming practices. With a strong emphasis on vaccine technology, Intervacc AB is dedicated to improving the well-being and productivity of livestock animals, thereby supporting the agricultural sector's growth and profitability.

Intervacc AB is primarily active in the biotechnology industry.

The main competitors of Intervacc AB in the market include other companies operating in the field of animal health and vaccines. Some of the key competitors of Intervacc AB include Zoetis Inc., Merck Animal Health, Elanco Animal Health, Boehringer Ingelheim, and Virbac. These companies also focus on developing innovative solutions and vaccines for animal diseases.

Intervacc AB is a biotechnology company based in Sweden, specializing in the development and commercialization of vaccines for infectious animal diseases. Founded in 1983, Intervacc has a rich history in the field of animal health and vaccine research. The company's expertise lies in the improvement of vaccine formulas, resulting in effective immunization against diseases such as Strangles and Equine Influenza in horses. With a strong commitment to scientific innovation and animal welfare, Intervacc AB continues to work towards the prevention and control of infectious diseases in animals, ensuring the wellbeing of livestock and pets worldwide.

Intervacc AB, a prominent stock company, has achieved several noteworthy milestones. One such significant accomplishment includes the successful completion of clinical trials for its novel Strangvac® vaccine, designed to combat equine strangles. Furthermore, Intervacc AB obtained a marketing authorization for Strangvac® from the European Medicines Agency, permitting commercialization across the European Union. The company has also secured substantial funding through various partnerships and collaborations, reinforcing its financial stability and promoting further research and development endeavors. With these achievements, Intervacc AB has demonstrated its pioneering efforts in the field of animal health, establishing a strong reputation in the market.

Intervacc AB is primarily present in Sweden, where its headquarters is located. As a biotechnology company, Intervacc AB focuses on the development and commercialization of vaccines for animals. While the company's primary presence is in Sweden, its vaccines have global potential and can benefit regions and countries worldwide. Intervacc AB aims to expand its reach and establish collaborations and partnerships to deliver its innovative animal vaccines across different markets.

Intervacc AB represents values of innovation, dedication, and excellence in the field of biotechnology. The company is committed to developing safe and effective vaccines for both humans and animals. With a focus on preventing infectious diseases, Intervacc AB aims to improve global health and well-being. The corporate philosophy of Intervacc AB revolves around scientific expertise, research-driven development, and collaboration with industry partners. By prioritizing cutting-edge technology, quality assurance, and regulatory compliance, Intervacc AB strives to contribute to the advancement of healthcare.

Analysts currently set an average price target of 96.90 SEK for the Intervacc stock (median: 96.90 SEK), implying +7,689.4 % versus the latest price. The consensus is based on 9 analyst ratings.

Intervacc Analyst Price Targets 2026

9 analysts currently rate the Intervacc stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Intervacc to generate revenue of 17.70 M SEK and earnings per share of -0.18 SEK.

Intervacc Analyst Price Targets 2026

Converted at the current exchange rate, the Intervacc share trades at 0.11 EUR (1.27 SEK).

The Intervacc share (IVACC.ST) is listed on 3 stock exchanges, including: Frankfurt (2E9.F).

Intervacc AB is a Swedish biotechnology company focused on the development and marketing of vaccines for animals. The company was founded in 2010 and is headquartered in Stockholm, Sweden. The goal of Intervacc AB is to improve the health and well-being of animals by developing and marketing innovative vaccines that help prevent and treat diseases in animals. Intervacc AB specializes in the development of vaccines for animals and offers products for four different market segments: horses, cattle, pigs, and poultry. The product range currently includes four vaccine candidates in various stages of development and marketing. Each vaccine has been specifically developed for a particular animal species and disease. The first vaccine developed by Intervacc AB is Equilis StrepE, a vaccine for horses used to prevent strangles (an upper respiratory tract infection). The company has also developed vaccine candidates for cattle, pigs, and poultry. The cattle vaccine is a vaccine for preventing infections caused by E. coli bacteria, which can lead to serious illnesses in cattle. The pig vaccine is a vaccine for preventing Streptococcus suis, a bacterium that can cause severe illness in pigs. The poultry vaccine is a vaccine designed to protect against infections caused by Campylobacter jejuni, a bacterium that can cause severe gastrointestinal diseases in humans. Currently, Intervacc AB is working on developing new vaccine candidates for other animal species and diseases. The company has an experienced team of biologists, microbiologists, veterinarians, technicians, and other professionals who work closely together to develop vaccines that are safe and effective. The business strategy of Intervacc AB is to establish a strong presence in the animal vaccine market by developing and marketing innovative products that meet the needs of veterinarians, agricultural farms, and other customers. The company works closely with its customers to better understand their needs and ensure that its products meet their requirements. Intervacc AB has also formed strategic partnerships with other companies in the animal health industry to strengthen the distribution of its products and accelerate growth. The company continuously works on improving its technologies and processes to increase the efficiency and quality of its products. Overall, Intervacc AB is an innovative company specializing in the development and marketing of vaccines for animals. The company has developed a wide range of products for different animal species and diseases, and is continuously working on developing new products. With its strong presence in the animal vaccine market and strategic partnerships, Intervacc AB has built a solid foundation for future growth.

The expected revenue of Intervacc is 17.70 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Intervacc is -62.45 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Intervacc is currently -6.93. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Intervacc stock.

The price-to-sales ratio (P/S) of Intervacc is currently 24.45. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Intervacc stock.

The Eulerpool Quality Score for Intervacc is 3/10.

The ISIN of Intervacc is SE0009607252. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Intervacc is A2DP4W. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Intervacc is IVACC.ST. The ticker symbol is used to trade Intervacc shares on the stock exchange.

Intervacc paid dividends every year for the past 0 years.

Intervacc is assigned to the 'Health' sector.

The dividends of Intervacc are distributed in SEK.